Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
D000818:Animals; D001921:Brain / Q000378:metabolism; D002794:Choline / Q000627:therapeutic use; D002908:Chronic Disease; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D020149:Manganese Poisoning; D008550:Melatonin / Q000627:therapeutic use; D008715:Methionine / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010649:Phenylalanine / Q000627:therapeutic use; D011041:Poisoning / Q000503:physiopathology; D011736:Pyridoxine / Q000627:therapeutic use; D014364:Tryptophan / Q000627:therapeutic use; D014443:Tyrosine / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D014443:Tyrosine; D010649:Phenylalanine; D004295:Dihydroxyphenylalanine; D014364:Tryptophan; D008715:Methionine; D008550:Melatonin; D011736:Pyridoxine; D002794:Choline